Natural Capsules Limited announced that the Department of Drug Controller has ordered a temporary closure of its Pondicherry manufacturing plant following a regulatory lapse involving materials supplied to a customer with an expired drug license. The company is actively addressing compliance gaps and seeking revocation of the closure directive soon.
Natural Capsules Limited informed the exchanges that the Department of Drug Controller has directed a temporary shutdown of the company’s Pondicherry manufacturing facility, effective December 26, 2025. The action follows a regulatory non-compliance incident where materials were supplied to a customer whose drug license had expired.
In response, the company has initiated prompt corrective measures and is preparing the necessary documentation to seek revocation of the closure order at the earliest. The financial impact arising from the suspension is currently being assessed, as the plant remains non-operational until further regulatory clearance.
Notable Updates:
-
Authority involved: Department of Drug Controller
-
Date of receipt of order: December 26, 2025
-
Reason for action: Supply of materials to a customer with an expired drug license
-
Impact: Temporary closure of operations at the Pondicherry plant
-
Next steps: Submission of compliance documents and request for revocation of the order
The company emphasized that it remains fully cooperative with the authorities and is committed to ensuring adherence to all applicable drug manufacturing and licensing regulations.
Source: NSE Corporate Filings, BSE Announcements